Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

493 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.
Schellens JH, Heinrich B, Lehnert M, Gore ME, Kaye SB, Dombernowsky P, Paridaens R, van Oosterom AT, Verweij J, Loos WJ, Calvert H, Pavlidis N, Cortes-Funes H, Wanders J, Roelvink M, Sessa C, Selinger K, Wissel PS, Gamucci T, Hanauske AR. Schellens JH, et al. Among authors: pavlidis n. Invest New Drugs. 2002 Feb;20(1):83-93. doi: 10.1023/a:1014454821885. Invest New Drugs. 2002. PMID: 12003197 Clinical Trial.
Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9.
Schellens JH, Dombernowsky P, Cassidy J, Epelbaum R, Dirix L, Cox EH, Wanders J, Calabresi F, Paridaens R, Monfardini S, Wolff J, Loos WJ, Verweij J, Pavlidis N, Hanauske AR; EORTC Early Clinical Studies Group. Schellens JH, et al. Among authors: pavlidis n. Anticancer Drugs. 2001 Aug;12(7):583-90. doi: 10.1097/00001813-200108000-00004. Anticancer Drugs. 2001. PMID: 11487714 Clinical Trial.
Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials Group.
Verweij J, Wanders J, Nielsen AL, Pavlidis N, Calabresi F, ten Bokkel Huinink W, Bruntsch U, Piccart M, Franklin H, Kaye SB. Verweij J, et al. Among authors: pavlidis n. Ann Oncol. 1994 Apr;5(4):375-6. doi: 10.1093/oxfordjournals.annonc.a058847. Ann Oncol. 1994. PMID: 8075039 Free article. Clinical Trial.
Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.
McLeod HL, Murray LS, Wanders J, Setanoians A, Graham MA, Pavlidis N, Heinrich B, ten Bokkel Huinink WW, Wagener DJ, Aamdal S, Verweij J. McLeod HL, et al. Among authors: pavlidis n. Br J Cancer. 1996 Dec;74(12):1944-8. doi: 10.1038/bjc.1996.657. Br J Cancer. 1996. PMID: 8980394 Free PMC article. Clinical Trial.
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG).
Pavlidis N, Aamdal S, Awada A, Calvert H, Fumoleau P, Sorio R, Punt C, Verweij J, van Oosterom A, Morant R, Wanders J, Hanauske AR. Pavlidis N, et al. Cancer Chemother Pharmacol. 2000;46(2):167-71. doi: 10.1007/s002800000134. Cancer Chemother Pharmacol. 2000. PMID: 10972487 Clinical Trial.
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group.
Briasoulis E, Judson I, Pavlidis N, Beale P, Wanders J, Groot Y, Veerman G, Schuessler M, Niebch G, Siamopoulos K, Tzamakou E, Rammou D, Wolf L, Walker R, Hanauske A. Briasoulis E, et al. Among authors: pavlidis n. J Clin Oncol. 2000 Oct 15;18(20):3535-44. doi: 10.1200/JCO.2000.18.20.3535. J Clin Oncol. 2000. PMID: 11032596 Clinical Trial.
493 results